These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1424 related items for PubMed ID: 26224873

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
    Solberg NT, Waaler J, Lund K, Mygland L, Olsen PA, Krauss S.
    Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
    [Abstract] [Full Text] [Related]

  • 4. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL, Kim HP, Cho YW, Min DW, Cheon SK, Lim YJ, Song SH, Kim SJ, Han SW, Park KJ, Kim TY.
    Int J Cancer; 2019 Jan 15; 144(2):389-401. PubMed ID: 29978469
    [Abstract] [Full Text] [Related]

  • 5. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, Costa M.
    Cancer Res; 2013 May 15; 73(10):3132-44. PubMed ID: 23539443
    [Abstract] [Full Text] [Related]

  • 6. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
    Kang DW, Lee BH, Suh YA, Choi YS, Jang SJ, Kim YM, Choi KY, Min DS.
    Clin Cancer Res; 2017 Dec 01; 23(23):7340-7350. PubMed ID: 28939743
    [Abstract] [Full Text] [Related]

  • 7. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
    Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Palmer HG.
    Nat Med; 2012 Jun 01; 18(6):892-901. PubMed ID: 22610277
    [Abstract] [Full Text] [Related]

  • 8. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.
    Sci Signal; 2014 Nov 11; 7(351):ra107. PubMed ID: 25389372
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL, Ma WJ, Chen S, Wu XZ, Zhang HR, Zhang JH.
    Zhonghua Zhong Liu Za Zhi; 2016 Aug 11; 38(8):578-88. PubMed ID: 27531477
    [Abstract] [Full Text] [Related]

  • 14. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
    Prossomariti A, Piazzi G, Alquati C, Ricciardiello L.
    Cell Mol Gastroenterol Hepatol; 2020 Aug 11; 10(3):491-506. PubMed ID: 32334125
    [Abstract] [Full Text] [Related]

  • 15. APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.
    Tanaka N, Mashima T, Mizutani A, Sato A, Aoyama A, Gong B, Yoshida H, Muramatsu Y, Nakata K, Matsuura M, Katayama R, Nagayama S, Fujita N, Sugimoto Y, Seimiya H.
    Mol Cancer Ther; 2017 Apr 11; 16(4):752-762. PubMed ID: 28179481
    [Abstract] [Full Text] [Related]

  • 16. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.
    Int J Cancer; 2013 Aug 15; 133(4):984-96. PubMed ID: 23475782
    [Abstract] [Full Text] [Related]

  • 17. Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
    He F, Chen H, Yang P, Wu Q, Zhang T, Wang C, Wei J, Chen Z, Hu H, Li W, Cao J.
    Oncotarget; 2016 Dec 06; 7(49):81156-81171. PubMed ID: 27835604
    [Abstract] [Full Text] [Related]

  • 18. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
    Qazi AK, Hussain A, Khan S, Aga MA, Behl A, Ali S, Singh SK, Taneja SC, Shah BA, Saxena AK, Mondhe DM, Hamid A.
    Cancer Lett; 2015 Apr 01; 359(1):47-56. PubMed ID: 25554016
    [Abstract] [Full Text] [Related]

  • 19. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
    Chen G, Gao C, Gao X, Zhang DH, Kuan SF, Burns TF, Hu J.
    Mol Cancer Ther; 2018 Apr 01; 17(4):806-813. PubMed ID: 29167314
    [Abstract] [Full Text] [Related]

  • 20. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
    Wang Q, Zhou Y, Rychahou P, Harris JW, Zaytseva YY, Liu J, Wang C, Weiss HL, Liu C, Lee EY, Evers BM.
    Cancer Res; 2018 Jun 15; 78(12):3163-3175. PubMed ID: 29666061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.